Halozyme Therapeutics, Inc. HALO
$111.93
+2.05%
at last close
Financials (TTM)
- Revenue
- $1.66 billion
- Net Income
- $413.60 million
- Net Margin
- 24.86%
- Return on Equity
- 288.13%
- Debt-to-Equity
- —
- P/E Ratio
- 32.63
- Price / Book
- 86.72
- Price / Sales
- 7.48
Over the trailing twelve months, Halozyme Therapeutics, Inc. generated revenue of $1.66 billion and net income of $413.60 million, a net margin of 24.86%.
At the last closing price of $111.93, HALO trades at 32.63 times trailing earnings and 7.48 times sales, with a market capitalization of $12.45 billion.
Key Stats
- Last Close
- $111.93
- Market Cap
- $12.45 billion
- 52-Week Range
- $61.23 – $112.05
- Average Volume
- 2.21 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.